Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study.
Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT.
Yam C, et al. Among authors: kong e.
Cancer Res Commun. 2024 Oct 2. doi: 10.1158/2767-9764.CRC-24-0255. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 39356138
Free article.